{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:51:44Z","timestamp":1774277504880,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12094-015-1435-3","type":"journal-article","created":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T12:03:58Z","timestamp":1450181038000},"page":"956-961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["SEOM clinical guidelines in Hereditary Breast and ovarian cancer"],"prefix":"10.1007","volume":"17","author":[{"name":"On behalf of the SEOM Hereditary Cancer Working Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Llort","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Chirivella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Beatriz","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Teul\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lastra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,15]]},"reference":[{"issue":"11","key":"1435_CR1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from a prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"key":"1435_CR2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329\u201333.","journal-title":"J Clin Oncol"},{"key":"1435_CR3","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243\u201357.","journal-title":"N Engl J Med"},{"key":"1435_CR4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654\u201363.","journal-title":"J Clin Oncol"},{"key":"1435_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"F Couch","year":"2015","unstructured":"Couch F, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304\u201311.","journal-title":"J Clin Oncol"},{"key":"1435_CR6","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree A, Mills MA, Anderson MJ, Kobayashi Y, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;. doi: 10.1001\/jamaoncol.2015.2690 .","journal-title":"JAMA Oncol."},{"key":"1435_CR7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2014.56.6232","volume":"33","author":"X-A Phi","year":"2015","unstructured":"Phi X-A, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, et al. Magnetic resonance imaging improve breast screening sensitivity in BRCA mutation carriers age \u226550\u00a0years: evidence from an individual patient data meta-analysis. J Clin Oncol. 2015;33:349\u201356.","journal-title":"J Clin Oncol"},{"key":"1435_CR8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/ijc.29534","volume":"137","author":"S Saadatmand","year":"2015","unstructured":"Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). Int J Cancer. 2015;137:1729\u201338.","journal-title":"Int J Cancer"},{"issue":"3","key":"1435_CR9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66(3):489\u201399.","journal-title":"Eur Urol"},{"key":"1435_CR10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967\u201375.","journal-title":"JAMA"},{"key":"1435_CR11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547\u201353.","journal-title":"J Clin Oncol"},{"key":"1435_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"31","key":"1435_CR13","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804\u201310.","journal-title":"J Clin Oncol"},{"key":"1435_CR14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"1435_CR15","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/annonc\/mdt134","volume":"24","author":"BA Heemskerk-Gerritsen","year":"2013","unstructured":"Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24:2029\u201335.","journal-title":"Ann Oncol"},{"key":"1435_CR16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BA Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Coll\u00e9e JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136:668\u201377.","journal-title":"Int J Cancer"},{"key":"1435_CR17","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091\u20139.","journal-title":"J Clin Oncol"},{"issue":"Sup 8","key":"1435_CR18","doi-asserted-by":"crossref","first-page":"viii42","DOI":"10.1093\/annonc\/mdt328","volume":"24","author":"B Bonanni","year":"2013","unstructured":"Bonanni B, Lazzeroni M. Acceptability of chemoprevention trials in high-risk subjects. Ann Oncol. 2013;24(Sup 8):viii42\u20136.","journal-title":"Ann Oncol"},{"issue":"8","key":"1435_CR19","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","volume":"11","author":"D Cibula","year":"2011","unstructured":"Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11(8):1197\u2013207.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1435_CR20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","volume":"143","author":"J Kotsopoulos","year":"2014","unstructured":"Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CT, Eng C, Hereditary Breast Cancer Clinical Study Group, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Br Can Res Treat. 2014;143(3):579\u201386.","journal-title":"Br Can Res Treat"},{"issue":"17","key":"1435_CR21","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","volume":"33","author":"ML Telli","year":"2015","unstructured":"Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutationassociated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895\u2013901.","journal-title":"J Clin Oncol."},{"issue":"5s","key":"1435_CR22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/jco.2014.32.15_suppl.1005","volume":"32","author":"G Minckwitz von","year":"2014","unstructured":"von Minckwitz G, Hahnen E, Fasching PA, Hauke J, Schneeweiss A, Salat C, et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol. 2014;32(5s):1005.","journal-title":"J Clin Oncol."},{"key":"1435_CR23","doi-asserted-by":"crossref","first-page":"S3-01","DOI":"10.1158\/1538-7445.SABCS14-S3-01","volume":"75","author":"A Tutt","year":"2014","unstructured":"Tutt A, Ellis P, Kilburn LS, Gilett C, Pinder S, Abraham J, et al. TNT: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1\/2 breast cancer CRUK\/07\/012). Cancer Res Suppl. 2014;75:S3-01.","journal-title":"Cancer Res Suppl."},{"key":"1435_CR24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.14694\/EdBook_AM.2015.35.114","volume":"35","author":"DS Tan","year":"2015","unstructured":"Tan DS, Kaye SB. Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different? Am Soc Clin Oncol Educ Book. 2015;35:114\u201321.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"4","key":"1435_CR25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","volume":"30","author":"SB Kaye","year":"2012","unstructured":"Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1435_CR26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib\u00a0maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol."},{"issue":"2","key":"1435_CR27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.bjc.6604830","volume":"100","author":"KA Metcalfe","year":"2009","unstructured":"Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer. 2009;100(2):421\u20135.","journal-title":"Br J Cancer"},{"issue":"9","key":"1435_CR28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-148-9-200805060-00007","volume":"148","author":"E Warner","year":"2008","unstructured":"Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148(9):671\u20139.","journal-title":"Ann Intern Med"},{"key":"1435_CR29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jmedgenet-2015-103094","volume":"52","author":"RS Post Van der","year":"2015","unstructured":"Van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361\u201374.","journal-title":"J Med Genet"},{"key":"1435_CR30","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice guidelines in oncology. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp,2015 ."},{"issue":"10","key":"1435_CR31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1086\/656735","volume":"51","author":"AR Khan","year":"2010","unstructured":"Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the infectious diseases society of America Clinical Practice Guidelines. Clin Infect Dis. 2010;51(10):1147\u201356.","journal-title":"Clin Infect Dis"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-015-1435-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1435-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:35:15Z","timestamp":1718246115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-015-1435-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1007\/s12094-015-1435-3","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}